Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (579)	2/18/1998 10:11:00 PM
From: Brander	Read Replies (1) \| Respond to of 834

TXB is one of the highest rated speculative biotechs. It is ranked 4/118 in its sector by Zacks. It also is rated a strong buy by Zacks. All research reports out rate TXB as a speculative strong buy. The share dilution is not bad at all compared to other developing biotechs. The earnings report was also not bad, and revealed improvement in some areas. It was superior to other biotechs in a similar phase of development. They have one drug that could be approved very soon by the FDA. If so, financing will no longer be an issue. quote.yahoo.com

To: Bill Wexler who wrote (579)	2/19/1998 1:06:00 AM
From: Larry Liebman	Respond to of 834

Bill..I'm a bit confused by the assertion that TXB continues to "disappoint" investors. I pulled up a chart showing it selling at <$2 in 1996. If I'm not mistaken, it just hit a 52 week high. It has a candidate waiting for approval and announced positive Phase2 results in CHF/a "significant" market. As I read your assertion, I wondered if you were referring to TCLN rather than TXB. Best of luck with your short position. I took a small stake last week at 6 1/4. I'll take the other side at this time.